BioCryst Pharmaceuticals, Inc. revenue for the last year amounted to 331.41 M USD, the most of which — 331.41 M USD — came from its highest performing source at the moment, Oral Small Molecule and Protein Therapeutics, the year earlier bringing 270.83 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought BioCryst Pharmaceuticals, Inc. 288.36 M USD.